SCHEMBL22912783

SCHEMBL22912783

CCc1nc2ccc(C(=O)OC)cc2[nH]c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.57
ALDH1A1 P00352 3/20 0.57
LMNA P02545 1/20 0.57
HTT P42858 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
EGFR P00533 2/20 0.52
PARP1 P09874 3/20 0.50
BRD4 O60885 1/20 0.49
CSNK2A1 P68400 1/20 0.48
MMP2 P08253 1/20 0.48
MMP9 P14780 1/20 0.48
MMP8 P22894 1/20 0.48
MMP13 P45452 1/20 0.48
CYP2C9 P11712 1/20 0.47
HSD17B10 Q99714 2/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29395745 0.90 EGFR (0.56) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL22912726 0.90 EGFR (0.56) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL25099251 0.90 KDM4E (0.54) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL29397635 0.86 KDM4E (0.57) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL22912802 0.86 KDM4E (0.57) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL22963779 0.85 KDM4E (0.56) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL29396283 0.85 KDM4E (0.56) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL22912779 0.85 KDM4E (0.62) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL29396732 0.85 KDM4E (0.62) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL25098947 0.85 RAB9A (0.61) KDM4EALDH1A1L3MBTL1EGFRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025101892-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS AND USES THEREOF Astellas Engineered Small Molecules US, Incorporated (US) 2025-05-15 WO disclosed
US-20230372527-A1 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR ASTRAZENECA UK LIMITED (GB) 2023-11-23 US disclosed
CN-116348115-A Combination of antibody-drug conjugate and PARP1 selective inhibitor 阿斯利康(英国)有限公司 2023-06-27 CN disclosed
US-20230077316-A1 CTPS1 INHIBITORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2023-03-09 US disclosed
US-11325906-B2 Chemical compounds ASTRAZENECA AB (SE) 2022-05-10 US disclosed
WO-2022074617-A1 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR ASTRAZENECA UK LIMITED (GB) 2022-04-14 WO disclosed
CN-114144413-A PARP1 inhibitors 阿斯利康(瑞典)有限公司 2022-03-04 CN disclosed
US-20210040084-A1 CHEMICAL COMPOUNDS ASTRAZENECA UK LIMITED (GB) 2021-02-11 US disclosed
WO-2021013735-A1 PARP1 INHIBITORS ASTRAZENECA AB (SE) 2021-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040084-A1 CHEMICAL COMPOUNDS CYP11B2, CYP11B1, CYP4B1 KDM4E 544/4885ALDH1A1 123/4885LMNA 2818/4885
US-20230077316-A1 CTPS1 INHIBITORS AND USES THEREOF CTPS1, CTPS2, ECHS1 KDM4E 3325/4885ALDH1A1 1472/4885LMNA 3314/4885
US-20230372527-A1 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR PARP12, PARP11, PARP1 KDM4E 2263/4885ALDH1A1 1194/4885LMNA 2575/4885
US-11325906-B2 Chemical compounds CYP11B2, CYP11B1, CYP4B1 KDM4E 544/4885ALDH1A1 123/4885LMNA 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.